Categories:

• Agriculture and Forestry
• Automotive
• Biotechnology and Pharmaceuticals
• Chemicals
• Construction and Maintenance
• Consumer Goods and Services
• Electronics and Electrical
• Energy and Environment
• Food and Related Products
• Industrial Goods and Services
• Information Technology
• Materials
• Real Estate
• Telecommunications
• Textiles and Nonwovens
• Transportation and Logistics

Popular Tags:

• player
• mp4
• mp4 player
• screen
• player screen
• screen mp4
• 4gb
• player 4gb
• 4gb mp4
• card
• slot
• player card
• 18inch
• inch
• 15inch
• inch mp4
• inch player
• flash
• style
• builtin

Home › Sarepta Therapeutics Completes NDA Submission To FDA For Eteplirsen For The Treatment Of Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping

 

Sarepta Therapeutics Completes NDA Submission To FDA For Eteplirsen For The Treatment Of Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping

2015-07-01 08:07:56| drugdiscoveryonline Home Page

Sarepta Therapeutics, Inc., a developer of innovative RNA-targeted therapeutics, recently announced the completion of the rolling submission of a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for eteplirsen on June 26, 2015

Tags: to treatment submission fda

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»

18.05 Eastern North Pacific Tropical Weather Outlook 18.05 Atlantic Tropical Weather Outlook 18.05 M&S website and app hit by technical issue 18.05 Eastern North Pacific Tropical Weather Outlook 18.05 Atlantic Tropical Weather Outlook 18.05 Producers to be paid grid premiums for AngusLink beef scores 18.05 This Week in Agribusiness, May 18, 2024 18.05 This Week in Agribusiness, May 18, 2024 More »